TG Therapeutics, Inc. Stock News

Subscribers to  Chart of the Week  received this commentary on Sunday, September 8.

Biotech stocks have been rallying as funds load up. Five stocks have been outperforming the vast majority in the IBD database.

NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming data presentations, highlighting data from both the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 European Committee for Treatment and Research ...

TG Therapeutics exceeded Q2 Street consensus estimates, with Briumvi net sales of $72.6 million and total revenues of $73.5 million. Positive cash flow achieved one quarter ahead of my expectations, and full-year guidance range raised by $15 million at the mid-point of the range. TG secured a new $250 million credit facility to retire the old one, and it will use $100 million to buy back shares.

TG Therapeutics, Inc. (NASDAQ:TGTX ) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET Company Participants Michael Weiss - Chairman, Chief Executive Officer Adam Waldman - Chief Commercialization Officer Sean Power - Chief Financial Officer Jenna Bosco - Senior Vice President of Corporate Communications Conference Call Participants Roger Song - Jefferies Matt Kaplan - Ladenburg Thalma...

Last month, we took a look at three biotech stocks following a historically bullish month for biotech exchange-traded fund (ETF) SPDR S&P Biotech ETF (XBI).

TG Therapeutics stock popped Tuesday after the drugmaker unexpectedly reported a second-quarter profit, thanks to significantly lower R&D.

STAMFORD, Conn.--(BUSINESS WIRE)--HealthCare Royalty (“HCRx”), in conjunction with funds managed by Blue Owl Capital (“Blue Owl”), has entered into a $250 million term loan facility (the “Initial Term Loan”) with TG Therapeutics, Inc. (“TG”, NASDAQ: TGTX), a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treat...